| __timestamp | Alkermes plc | Ultragenyx Pharmaceutical Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 199905000 | 10811000 |
| Thursday, January 1, 2015 | 311558000 | 33001000 |
| Friday, January 1, 2016 | 374130000 | 64936000 |
| Sunday, January 1, 2017 | 421578000 | 99909000 |
| Monday, January 1, 2018 | 526408000 | 127724000 |
| Tuesday, January 1, 2019 | 599449000 | 161524000 |
| Wednesday, January 1, 2020 | 538827000 | 182933000 |
| Friday, January 1, 2021 | 560977000 | 219982000 |
| Saturday, January 1, 2022 | 605747000 | 278139000 |
| Sunday, January 1, 2023 | 689751000 | 309799000 |
| Monday, January 1, 2024 | 645238000 |
Cracking the code
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Alkermes plc and Ultragenyx Pharmaceutical Inc. have shown contrasting approaches to handling these costs. From 2014 to 2023, Alkermes consistently reported higher SG&A expenses, peaking at approximately $690 million in 2023. In contrast, Ultragenyx's expenses grew from a modest $11 million in 2014 to around $310 million in 2023, reflecting a more than 28-fold increase.
Despite Ultragenyx's rapid growth in expenses, Alkermes' expenses have been more stable, with a 3.5-fold increase over the same period. This suggests that Alkermes may have a more controlled approach to managing its SG&A costs. Investors and industry analysts should consider these trends when evaluating the financial health and operational efficiency of these companies.
Who Optimizes SG&A Costs Better? Novo Nordisk A/S or Alkermes plc
Operational Costs Compared: SG&A Analysis of AstraZeneca PLC and Alkermes plc
Cost Management Insights: SG&A Expenses for Vertex Pharmaceuticals Incorporated and Ultragenyx Pharmaceutical Inc.
Comparing SG&A Expenses: Teva Pharmaceutical Industries Limited vs Ultragenyx Pharmaceutical Inc. Trends and Insights
Breaking Down SG&A Expenses: Neurocrine Biosciences, Inc. vs Alkermes plc
Operational Costs Compared: SG&A Analysis of BioMarin Pharmaceutical Inc. and Alkermes plc
SG&A Efficiency Analysis: Comparing Exelixis, Inc. and Alkermes plc
Alkermes plc and CRISPR Therapeutics AG: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Alkermes plc or Vericel Corporation
Comparing SG&A Expenses: Alkermes plc vs Travere Therapeutics, Inc. Trends and Insights
Comparing SG&A Expenses: Ultragenyx Pharmaceutical Inc. vs Perrigo Company plc Trends and Insights
Selling, General, and Administrative Costs: Ultragenyx Pharmaceutical Inc. vs Taro Pharmaceutical Industries Ltd.